When: Positive CMS CGM coverage decision

Then: Re-engage position toward benchmark weight (requires one of three triggers)

TRIM - Reduce long position by 25-40% into rallies between $113-$117; maintain core holding due to dividend coverage and defensive profile but do not add exposure at current levels.

• Q2 2026 net income collapsed 39% sequentially, translating into hundreds of millions in lost earnings; integration timeline of 'one or two quarters' remains uncertain
• $22.8 billion in net new debt pushed debt-to-equity from approximately 26% to 63.2%, with interest expense rising in a higher-for-longer rate environment
• Confirmed MACD bearish cross with histogram widening to negative 1.15 as of late August; RSI declined from 78 to 48.6 in seven sessions
• Price is below the 10 EMA at $111.17 and only $3.50 (approximately 1.2 ATRs) above the 200 SMA
• With beta of 0.581 and compressed ATR, a single negative earnings revision or adverse CMS decision could push price through $105 to retest the 50 SMA at $103.90
• Forward P/E of 17.9x is consensus-dependent; if integration underperforms, the multiple doesn't hold—it expands because earnings collapse
• Forward EPS of $6.06 versus trailing $3.09 implies near-doubling of earnings; if this consensus is wrong, the denominator collapses and valuation deteriorates
• Free cash flow covers dividends at 1.6x today, but rising interest expense will compress coverage ratios going forward
• Libre Duo FDA clearance, LAA closure CE mark, and CMS CGM coverage are real catalysts, but timelines for revenue/earnings conversion are unspecified and CMS decision is explicitly binary
• Stock has underperformed the healthcare sector over the trailing year despite positive catalysts, suggesting the market is not yet convinced of the integration story
• The gap between 52-week high of $137 and current consolidation around moving averages indicates the catalyst narrative remains contested, not confirmed
• Zero retail interest (no Reddit posts) provides no momentum tailwind and does not indicate quiet institutional accumulation

→ vs aggressive: Integration noise framing dismisses real earnings loss; 'one or two ugly quarters' is an unknown timeline management is gambling on, not a confirmed recovery schedule

→ vs aggressive: Leverage described as 'fuel, not poison' ignores $22.8 billion in net new debt and D/E jumping to 63.2% in a higher-for-longer rate environment with only 12% December cut probability

→ vs aggressive: MACD bearish cross with histogram at negative 1.15 and RSI at 48.6 indicate deteriorating momentum, not 'selling pressure exhausted'; three momentum indicators flashing warnings in unison is a risk signal

→ vs aggressive: Claim that price above 50 and 200 SMAs means intact uptrend ignores that $3.50 cushion is only 1.2 ATRs—insufficient protection against a single negative catalyst

→ vs aggressive: 5% downside to 50 SMA versus 8% upside to August high is roughly symmetric risk-reward, not asymmetric; ignores the gap to $137 52-week high as the true ceiling

→ vs aggressive: Stop at $117.34 is not uncertainty—it's a tactical trim plan above entry because the trader is reducing size, not making a directional bet against the stock

→ vs aggressive: Forward P/E of 17.9x is consensus and depends on successful integration; if consensus is wrong, the multiple doesn't compress to 17.9x—it expands as earnings collapse

→ vs aggressive: Treating every catalyst as a confirmed positive outcome ignores variance; CMS CGM coverage is explicitly binary, and regulatory wins are not earnings

→ vs aggressive: Dividend coverage at 1.6x is fine today but compresses with elevated leverage and rising interest expense; dividend growth slowdown is a secondary risk not being priced

→ vs aggressive: Zero Reddit posts indicates no retail interest or momentum tailwind, not quiet institutional accumulation; off-radar stocks can simply stagnate

Trim 25-40% into rallies between $113-$117, maintain core position of 50-75% of benchmark weight with defined re-entry and exit triggers

• Forward EPS $6.06 versus trailing $3.09 embeds a recovery story; if Q3 prints soft and EPS revises to $5.40, the 17.9x multiple becomes 20x and upside thesis evaporates
• Q2 shows revenue down only 2.6% sequentially with expenses up 15% - this is an expense problem, not a demand problem; integration pain is finite, not structural rot
• Net debt up $22.8 billion, D/E at 63.2% is elevated but not distressed given $7.21B TTM FCF and 1.6x dividend coverage
• Price above rising 50 and 200 SMAs but MACD showing bearish cross with widening negative histogram and RSI rolling over without oversold tag
• Catalyst pipeline (Libre Duo FDA, LAA CE mark, Similac whole milk, CMS CGM decision) is real but regulatory approvals don't immediately materialize into revenue; CMS CGM decision is explicitly binary with no bear scenario provided
• FCF dividend coverage minimum of 1.3x for two consecutive quarters should trigger re-evaluation of defensive thesis
• Stop level at $117.34 above entry is well-calibrated; if price breaks that level on volume, catalyst narrative is converting to price action

→ vs aggressive: Forward P/E of 17.9x is a projection, not a current relationship; treating consensus as fact is a critical distinction - if Q3 prints soft and EPS revises to $5.40, the 17.9x multiple becomes 20x and upside thesis evaporates

→ vs aggressive: Listing catalysts (Libre Duo FDA, LAA CE mark, Similac whole milk, CMS CGM) and treating them all as confirmed positives is misleading; regulators don't approve products and revenue materializes next week, insulin pump integrations take years, and the CMS CGM decision is explicitly binary with no bear scenario addressed

→ vs aggressive: 'Zero Reddit posts' framing retail silence as institutional accumulation is unsupported; zero interest means no-man's land, not a setup for explosive upside - it's range-bound chop with technicals leaning toward the lower side of range

→ vs conservative: Q2 framing as structural rot is wrong; 2.6% sequential revenue decline with 15% expense increase is an expense problem, not demand deterioration - acquisition integration is a known finite process, not permanent structural damage

→ vs conservative: 63.2% D/E is elevated but not catastrophic for Abbott given $7.21B TTM FCF and 1.6x dividend coverage - this is elevated leverage, not distressed leverage; interest expense is a margin headwind, not a solvency issue

→ vs conservative: Framing the trim as a directional short is incorrect; the trader is reducing position 25-40% but maintaining 50-75% of benchmark weight - that's risk management with retention, not a bearish bet on a contested forward thesis